Merus BV (NASDAQ:MRUS) is a dynamic biotechnology company focused on developing innovative, full-length human bispecific and trispecific antibody therapeutics. With a deep commitment to addressing unmet medical needs, Merus is dedicated to advancing a broad pipeline of therapies aimed at treating various types of cancer. Unique to its approach is the use of its proprietary Biclonics® and Triclonics® technology platforms, designed to produce antibodies that can engage multiple targets simultaneously, offering potential for more effective treatments. The company strives to transform cancer treatment paradigms, working tirelessly toward achieving dramatic improvements in patient outcomes.